IN8BIO, Inc.NASDAQ INAB Stock Report

IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer. Its lead product candidates are in phase I clinical trials. Its lead product candidate, INB-200, is for the treatment of patients with newly diagnosed glioblastoma (GBM), and INB-100, for the treatment of patients with leukemia that are undergoing hematopoietic stem cell transplantation (HSCT). In addition, the Company's DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-400, focused on addressing GBM and other solid tumor types. Its DeltEx platform has enabled a pipeline of preclinical and clinical product candidates, which are designed to target and potentially eradicate disease, to improve patient outcomes. Its platform is designed to overcome various challenges associated with expansion, genetic engineering and manufacturing of gamma-delta T cells.